Kava (Kavalactones).

Isolated kavalactones are fat-soluble and need micelle transport to cross the intestinal wall, which is why traditional preparations use coconut fat. A medium-chain lipid base supplies that vehicle.

Kavalactones modulate GABA-A sites and damp voltage-gated sodium and calcium channels, while theanine acts on glutamate handling and cortical alpha rhythm. The routes are separate, so the pairing adds breadth rather than doubling one mechanism.

Apigenin occupies the benzodiazepine site on GABA-A while kavalactones modulate the same receptor elsewhere on the complex. The relaxing effect is additive and should be dosed as such.

Valerenic acid is a positive allosteric modulator at GABA-A beta subunits, the receptor family kavalactones also modulate. Combining them raises central inhibitory tone more than either alone.

Passionflower flavonoids raise GABAergic tone at the same receptor complex the kavalactones act on. That makes the pairing genuinely additive on normal relaxation.

Lemon balm rosmarinic acid slows GABA breakdown so more transmitter stays in the synapse, while kavalactones make the receptor more responsive to it. Ligand availability and receptor sensitivity are different levers on the same synapse.

Magnesium sits in the NMDA channel pore and limits excitatory calcium entry, and glycine is itself an inhibitory transmitter. Kavalactones lower excitability from the GABA and channel side, so the two work opposite ends of the same balance.

Adenosine receptor blockade raises cortical arousal, the opposite of what GABA-A modulation by kavalactones produces. Each blunts the other, so the combination wastes both.

Hyperforin induces CYP3A4 and efflux transporters, speeding kavalactone clearance and lowering the exposure a given dose delivers. Both also act on central tone, so the pairing loses potency while stacking effects.

Melatonin acts on circadian receptors that set timing, while kavalactones lower arousal in the moment. Timing and arousal are independent contributors to normal sleep onset.

The isolated kavalactone fraction carries the receptor activity attributed to the whole root, modulating GABA-A complexes rather than acting as a direct agonist. Oral GABA crosses into the central nervous system poorly in adults, so the pairing shares a theme more than a demonstrated stack. Anything pushing GABAergic tone the same way counts as additive.

Two positive modulators of one receptor complex, acting at separate sites, combine in principle. Apigenin comes with chamomile and other flavone sources; the kavalactone fraction brings the styrylpyrones. Expect drowsiness to add when both are in an evening formula.

Magnolia lignans and kavalactones both increase chloride conductance through GABA-A receptors in preparation studies. Stacking them concentrates several modulators on one system. This is a caution about additive sedation rather than a claimed benefit.

Glycine acts at its own inhibitory receptor and as an NMDA co-agonist, separate from the GABA-A complex. Both sit on the calming side of the ledger and both appear in evening formulas. The combination has not been measured, so the row records direction only.

Taurine interacts with both inhibitory receptor families at physiological concentration, placing it alongside kavalactones in direction if not in strength. Oral taurine's effect on central tone in adults is modest. Read this as directional.

5-HTP raises serotonin synthesis and, downstream, melatonin, a separate route to sleepiness from GABA-A modulation. Sleep blends combine the two axes deliberately. Two sedating routes in one capsule may produce more drowsiness than either alone; the pair has not been measured together.

Tryptophan feeds serotonin and melatonin synthesis while kavalactones act at the receptor level on the inhibitory side. The two approach evening calm from different directions. No combination trial exists for the pair.

Withanolide extracts and kavalactone extracts appear together in evening formulas and both lean sedative. Drowsiness from the two can add. The basis is convention plus shared direction, not a measured interaction.

An isolated kavalactone fraction is a resin, not a water-soluble powder, so it separates out of an aqueous base without an emulsifier. Lecithin phospholipids keep it dispersed. This is delivery chemistry and says nothing about how much reaches the bloodstream.

Phosphatidylcholine forms the micellar and bilayer structures that carry poorly water-soluble compounds through the gut. The kavalactone fraction is exactly that kind of material. It functions as a vehicle rather than as a second active.

Piperine slows some CYP and UGT activity and can raise circulating levels of co-administered plant compounds. Kavalactones are cleared by exactly those phase I and phase II routes, so a co-formulated piperine could increase exposure. The direction and size have not been measured for this pair, and increased exposure is not automatically desirable.

Phase II metabolism conjugates reactive intermediates with glutathione, and cysteine availability sets the rate of glutathione synthesis. NAC supplies that cysteine. This is mechanistic reasoning about hepatic handling and has not been tested as a combination in people, so it does not substitute for product-level guidance on liver monitoring.

Silymarin inhibits certain CYP and UGT isoforms in laboratory systems. Since kavalactones are cleared through those routes, the combination could change exposure in either direction. The row flags a plausible pharmacokinetic interaction, not a benefit.

Glutathione conjugation handles reactive metabolites produced during hepatic oxidation of plant constituents. Oral glutathione raises systemic pools only modestly, which limits how much the pairing changes. It is mechanistic reasoning at the bottom confidence band.

Curcumin alters the activity of several metabolising enzymes and efflux transporters in laboratory systems, which could in principle change kavalactone handling. Its own oral absorption is low, which limits how much of that reaches the liver. The row records the possibility rather than an established effect.